This site is intended for healthcare professionals only
LoginRegister
Lupin Gets Expert Committee Nod To Conduct Phase I Trial of Certolizumab Pegol, IGRA TB Test Made MandatoryLupin to Conduct BE Study for Synthetic Semaglutide Tablets in 3 Strengths
Sun Pharma Fails to Secure CDSCO Nod for BE, Phase III Waiver on Sitagliptin, Glimepiride, Metformin FDCSun Pharma Gets CDSCO Panel Nod for Active PMS of Fexuprazan Hydrochloride Tablets
Chemists Body Warns of 55% Rise in Drug Abuse, Calls for Ban on 10-Minute Prescription Drug DeliveryChemists' Body Warns of 55% Rise in Drug Abuse, Calls for Ban on 10-Minute Prescription Drug...
Cohance Lifesciences announces USD 10 mn investment in cGMP Bioconjugation Suite at NJ BioCohance Lifesciences announces USD 10 mn investment in cGMP Bioconjugation Suite at NJ Bio
Bayer, Kumquat Biosciences ink pact to develop, commercialize KRAS G12D inhibitorBayer, Kumquat Biosciences ink pact to develop, commercialize KRAS G12D inhibitor
Setback to Torrent: CDSCO Panel Rejects Phase III Waiver Plea for Prucalopride Over Safety Data GapsSetback to Torrent: CDSCO Panel Rejects Phase III Waiver Plea for Prucalopride Over Safety Data Gaps
India targets new markets for pharma export growth amid US tariffs concernsNo additional tariffs imposed on Indian exports to US in pharma sector: Govt
Zydus Lifesciences Reports Rs 6,573.7 Cr Revenue in Q1 FY26, Net Profit Rises 3%Zydus Lifesciences Reports Rs 6,573.7 Cr Revenue in Q1 FY26, Net Profit Rises 3%
USFDA concludes inspection at Zydus Lifesciences SEZ II, Ahmedabad plantUSFDA concludes inspection at Zydus Lifesciences SEZ II, Ahmedabad plant
Sanofi India appoints Richa Bakshi as People Excellence LeadSanofi India appoints Richa Bakshi as People Excellence Lead
Zydus Lifesciences Reports Rs 6,573.7 Cr Revenue in Q1 FY26, Net Profit Rises 3%Zydus Lifesciences gets 4 USFDA observations for Baddi plant
Pharma Firm, Director Under ED Lens Over Alleged Rs 60 Crore PNB FraudPharma Firm, Director Under ED Lens Over Alleged Rs 60 Crore PNB Fraud
X